Document ID: FDA-2019-N-0218-0004
Agency: fda
Document Type: Notice
Title: Pulmonary-Allergy Drugs Advisory Committee; Cancellation
Posted Date: 2019-04-02T04:00Z

[Federal Register Volume 84, Number 63 (Tuesday, April 2, 2019)]
[Notices]
[Page 12626]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-06389]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-0218]

Pulmonary-Allergy Drugs Advisory Committee; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The meeting of the Pulmonary-Allergy Drugs Advisory Committee 
scheduled for March 27, 2019, has been cancelled. This meeting was 
announced in the Federal Register of January 31, 2019. This meeting has 
been cancelled due to new information regarding the application. The 
Agency intends to continue evaluating the application and, as needed, 
will announce future meeting dates in the Federal Register.

FOR FURTHER INFORMATION CONTACT: Cindy Chee, Center for Drug Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, Fax: 
301-847-8533, email: [email protected], or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), and follow the prompts to the desired center or product area. 
Please call the Information Line for up-to-date information on this 
meeting, which was announced in the Federal Register of January 31, 
2019 (84 FR 748).

    Dated: March 28, 2019.
Lowell J. Schiller,
Acting Associate Commissioner for Policy.
[FR Doc. 2019-06389 Filed 4-1-19; 8:45 am]
 BILLING CODE 4164-01-P